Vcanbio Cell & Gene Engineering Corp Ltd - Asset Resilience Ratio

Latest as of September 2025: 10.22%

Vcanbio Cell & Gene Engineering Corp Ltd (600645) has an Asset Resilience Ratio of 10.22% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read Vcanbio Cell & Gene Engineering Corp Ltd balance sheet liabilities for a breakdown of total debt and financial obligations.

Liquid Assets

CN¥543.18 Million
≈ $79.48 Million USD Cash + Short-term Investments

Total Assets

CN¥5.32 Billion
≈ $778.11 Million USD All company assets

Resilience Assessment

Moderate
Financial Resilience Level

Asset Resilience Ratio Trend (1996–2019)

This chart shows how Vcanbio Cell & Gene Engineering Corp Ltd's Asset Resilience Ratio has changed over time. See net assets of Vcanbio Cell & Gene Engineering Corp Ltd for net asset value and shareholders' equity analysis.

Liquid Assets Composition Over Time

This chart breaks down Vcanbio Cell & Gene Engineering Corp Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Vcanbio Cell & Gene Engineering Corp Ltd (600645) market capitalisation.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents CN¥0.00 0%
Short-term Investments CN¥543.18 Million 10.22%
Total Liquid Assets CN¥543.18 Million 10.22%

Asset Resilience Insights

  • Moderate Liquidity: Vcanbio Cell & Gene Engineering Corp Ltd has 10.22% of assets in liquid form.
  • While adequate for normal operations, this level may limit flexibility during economic stress.
  • The company has significant short-term investments, indicating active treasury management.

Vcanbio Cell & Gene Engineering Corp Ltd Industry Peers by Asset Resilience Ratio

Compare Vcanbio Cell & Gene Engineering Corp Ltd's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Royalty Pharma Plc
NASDAQ:RPRX
Biotechnology 0.10%
Tubize-Fin
BR:TUB
Biotechnology 0.05%
Shanghai Allist Pharmaceuticals Co. Ltd. A
SHG:688578
Biotechnology 30.29%
Hebei Changshan Biochem Pharma
SHE:300255
Biotechnology -0.03%
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252
Biotechnology 4.52%
Shanghai Junshi Biosciences Co Ltd
SHG:688180
Biotechnology 4.28%
Spyre Therapeutics Inc.
NASDAQ:SYRE
Biotechnology 83.49%
Soleno Therapeutics Inc
NASDAQ:SLNO
Biotechnology 41.74%

Annual Asset Resilience Ratio for Vcanbio Cell & Gene Engineering Corp Ltd (1996–2019)

The table below shows the annual Asset Resilience Ratio data for Vcanbio Cell & Gene Engineering Corp Ltd.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2019-12-31 8.22% CN¥401.67 Million
≈ $58.78 Million
CN¥4.89 Billion
≈ $715.35 Million
+7.75pp
2017-12-31 0.47% CN¥14.00 Million
≈ $2.05 Million
CN¥3.00 Billion
≈ $438.99 Million
-3.83pp
2016-12-31 4.30% CN¥129.10 Million
≈ $18.89 Million
CN¥3.00 Billion
≈ $439.53 Million
+4.30pp
2015-12-31 0.00% CN¥4.25K
≈ $621.91
CN¥2.82 Billion
≈ $412.09 Million
-15.20pp
2014-12-31 15.20% CN¥367.39 Million
≈ $53.76 Million
CN¥2.42 Billion
≈ $353.67 Million
+9.70pp
2010-12-31 5.50% CN¥42.45 Million
≈ $6.21 Million
CN¥771.69 Million
≈ $112.92 Million
+0.65pp
2008-12-31 4.85% CN¥31.61 Million
≈ $4.63 Million
CN¥651.74 Million
≈ $95.37 Million
+1.13pp
2007-12-31 3.72% CN¥21.90 Million
≈ $3.20 Million
CN¥588.65 Million
≈ $86.14 Million
+3.71pp
2006-12-31 0.01% CN¥50.00K
≈ $7.32K
CN¥579.39 Million
≈ $84.78 Million
-0.22pp
2003-12-31 0.23% CN¥1.45 Million
≈ $212.24K
CN¥636.09 Million
≈ $93.08 Million
-0.12pp
2002-12-31 0.35% CN¥1.99 Million
≈ $290.86K
CN¥567.42 Million
≈ $83.03 Million
-3.41pp
2001-12-31 3.76% CN¥29.35 Million
≈ $4.30 Million
CN¥781.36 Million
≈ $114.34 Million
-1.47pp
2000-12-31 5.23% CN¥35.45 Million
≈ $5.19 Million
CN¥678.36 Million
≈ $99.26 Million
+1.14pp
1999-12-31 4.09% CN¥26.97 Million
≈ $3.95 Million
CN¥659.36 Million
≈ $96.49 Million
+2.53pp
1998-12-31 1.56% CN¥10.50 Million
≈ $1.54 Million
CN¥673.16 Million
≈ $98.50 Million
+0.67pp
1997-12-31 0.89% CN¥5.37 Million
≈ $785.60K
CN¥606.51 Million
≈ $88.75 Million
-1.47pp
1996-12-31 2.36% CN¥10.17 Million
≈ $1.49 Million
CN¥431.22 Million
≈ $63.10 Million
--
pp = percentage points

About Vcanbio Cell & Gene Engineering Corp Ltd

SHG:600645 China Biotechnology
Market Cap
$1.70 Billion
CN¥11.64 Billion CNY
Market Cap Rank
#6906 Global
#1604 in China
Share Price
CN¥24.87
Change (1 day)
-3.87%
52-Week Range
CN¥21.44 - CN¥32.94
All Time High
CN¥68.93
About

Vcanbio Cell & Gene Engineering Corp., Ltd, together with its subsidiaries, engages in the preparation and storage of cell detection tests in the People's Republic of China. It offers cell test preparation and storage services for umbilical cord blood hematopoietic stem cells, umbilical cord mesenchymal stem cells, placental pluripotent stem cells, immune cells, adipose stem cells, and dental ste… Read more